Navigation Links
VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
Date:10/7/2010

SAN DIEGO and SEATTLE, Oct. 7 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated that VTX-1463 significantly improved allergy symptoms based on Total Nasal Symptom Scores (TNSS) compared to placebo (p=0.012). TNSS is the standard endpoint used in allergy trials that takes into account nasal congestion, itching, sneezing and rhinorrhea. VTX-1463 is a selective TLR8 agonist that is delivered intranasally on a weekly basis.

"It's encouraging to see such robust results from this new selective TLR8 agonist," said Friedrich Horak, M.D., Professor of the Medical University Vienna and Vienna Challenge Chamber (VCC) in Vienna, Austria, and principal investigator of this study. "Given that allergic rhinitis impacts a substantial portion of the overall population, a potential drug like VTX-1463 that is administered intranasally once a week could provide an important advantage for patients."

The clinical trial assessed safety and efficacy of VTX-1463 in a randomized, placebo controlled study in 80 patients with confirmed allergy to grass pollen in the Vienna Challenge Chamber. VTX-1463 was evaluated as a stand-alone agent administered once-weekly in four doses intranasally. Further details of the trial and results will be presented at an upcoming scientific meeting.

"These data provide clinical proof-of-concept for further development of VTX-1463 in allergic rhinitis as well as the rationale to potentially explore other allergic indications," said Robert Hershberg, M.D., Ph.D., Co-founder and Chief Medical Officer at VentiRx. "The VTX-1463 data combined with recent data generated with VTX-2337 in oncology validates TLR8 as an imp
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
7. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
9. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
10. Transcept Pharmaceuticals to Present at BIO Investor Forum
11. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
... 31, 2011 Nephros, Inc. (OTC Bulletin Board: ... marketing filtration products for therapeutic applications, infection control, and ... Form S-1 for its previously announced rights offering to ... 2011 by the Securities and Exchange Commission. ...
Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... YORK (17 April 2014) Population Council scientists and their ... safe, stable, and can prevent the transmission of multiple ... rectum in animals: HIV, herpes simplex virus 2 (HSV-2), ... the first data that the gel is effective against ... efficacy in the vagina against all three viruses of ...
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... Professor Patrick Johnston, whose work has transformed cancer care ... of the European Academy of Cancer Sciences., The Academy, ... body of highly distinguished oncologists and cancer researchers which ... cancer in Europe. , Professor Johnston, whose leadership has ... the bottom of the UK league table to near ...
(Date:4/16/2014)... 2014 The Translational Genomics Research Institute (TGen) recently ... Dinner for their support of TGen,s research into brain, ... 28 in Scottsdale. , Catherine Ivy, Founder and President ... John S. McCain Leadership Award, named for U.S. Sen. ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... 18, 2008 TAP Pharmaceutical Products Inc. today reported ... new drug TAK-390MR, the first proton pump inhibitor (PPI) ... patients with erosive esophagitis (EE) and in maintenance of ... Disease Week (DDW) annual meeting in San Diego. , ...
... the 2000 census, Americans office workers spend an average ... work stations. Many recent studies on job satisfaction have ... environments, often under artificial light in windowless offices, report ... can employers make office environments more conducive to productivity ...
... 19 Volcano Corporation,(Nasdaq: VOLC ), a ... Optical Coherence Tomography (OCT) products designed,to enhance the ... said today that it will be participating in ... May 20., The presentation by Scott Huennekens, ...
... and progression of prostate cancer have eluded scientists ... have identified a specific gene expression profile of ... future treatments. The findings, published in BioMed Centrals ... that are differentially expressed in certain prostate cancer ...
... CHICAGO, May 19 SmithAmundsen LLC is pleased,to announce ... Chicago office,has been elected partner, effective May 17, 2008., ... Health Care practice group,focusing her work on health care ... Health Care Agencies, involving,the defense of both nursing and ...
... 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... rejoined the company in a part-time position ... owned subsidiary of Alexza. Mr.,Williams will have ... Singapore and establishing potential joint ventures in,Singapore. ...
Cached Medicine News:Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Greener offices make happier employees 2Health News:Volcano Corporation Presentation at JMP Conference to be Webcast 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:SmithAmundsen Elects New Partner, Linda F. Newman 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model....
Delicate lightly curved tips, 1 x 2 mouse style teeth. Serrated handle with polished finish....
Straight tubular shaft with delicate 1.5 mm oval jaws. Squeeze barrel style handle with tip guard and polished finish....
Three 2 mm prongs with 0.1 mm angled tips. 20 gauge (.89 mm) diameter shaft. Lightweight Wilson style squeeze handle with dull finish. Most popular size or model....
Medicine Products: